'[HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $27

Benzinga Newsdesk www.benzinga.com Negative 76.2%

Neg 76.2% Neu 0% Pos 0%

HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $34 to $27.